Evidence Hub

Comparative study of the microbiological activity of pazufloxacin, levofloxacin and moxifloxacin

O. Kondratenko, R. R. Galieva

Meditsinskiy sovet = Medical Council, 2025

Abstract

Introduction. Increasing antibiotic resistance is an important global problem. One of the most common classes of antibacterial drugs used in therapeutic practice are fluoroquinolones. Such drugs as levofloxacin, moxifloxacin, and pazufloxacin are the most promising for the treatment of a wide range of infections. Pazufloxacin has a good clinical effect in the treatment of infections resistant to other antibiotics. With respect to levofloxacin and moxifloxacin, there are criteria for determining sensitivity and significant experience in clinical and microbiological studies indicating their effectiveness, but with respect to pazufloxacin, there are few such studies and currently there are no criteria for interpreting the diameters of growth retardation zones and/or indicators of the values of the minimum suppressive concentration (MSC). Aim. To evaluate the distribution of the values of the minimum suppressive concentrations of drugs of the fluoroquinolone group: pazufloxacin, levofloxacin, moxifloxacin in relation to 200 clinical isolates of microorganisms. Materials and methods. We selected 200 bacterial strains isolated from patients from various regions of the Russian Federation. Among them are 20 strains of Pseudomonas aeruginosa, excluding MBL producers, 20 – Klebsiella pneumoniae, excluding MBL producers, 20 – Streptococcus pneumoniae, 20 – Enterococcus faecalis, 20 – Enterococcus faecium, 20 – Escherichia coli, excluding MBL producers, 20 – Proteus spp., excluding MBL…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free